NCT00586105View on ClinicalTrials.gov

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

PHASE3CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)

Trial Locations (8)

112

Taipei

333

Taoyuan District

10002

Taipei

70428

Tainan City

100021

Beijing

200032

Shanghai

200127

Shanghai

210003

Nanjing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY